---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-249055"
form_type: "8-K"
ticker: "AURA"
cik: "0001501796"
company_name: "Aura Biosciences, Inc."
filed_at: "2023-10-02T23:59:59+00:00"
generated_at: "2026-06-10T06:20:57.007703+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aura Biosciences names new CMO/President of R&D and CTO; CMO Rich transitions to advisor

## Summary
- J. Jill Hopkins appointed CMO and President of R&D, effective Oct 16, 2023; prior roles at Novartis, Gyroscope, Roche-Genentech.
- Mark Plavsic appointed CTO; 30 years experience including Fate Therapeutics, Sanofi Genzyme, AstraZeneca.
- Cadmus Rich resigns as CMO effective Oct 16; will serve as Senior Clinical Advisor through Nov 7, then consultant for 9 months.
- Hopkins receives annual base salary of $525k, sign-on bonus up to $200k, and equity grants of 200k options and 135k RSUs.

## SEC filing metadata
- accession: 0001193125-23-249055
- form_type: 8-K
- ticker: AURA
- cik: 0001501796
- company_name: Aura Biosciences, Inc.
- filed_at: 2023-10-02T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501796/000119312523249055/0001193125-23-249055-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501796/000119312523249055/d479220d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-249055
- JSON: https://secwatch.observer/filing/0001193125-23-249055.json
- Plain text: https://secwatch.observer/filing/0001193125-23-249055.txt

## Key facts
- Executive change
  J. Jill Hopkins was appointed as Chief Medical Officer and President of Research & Development at Aura Biosciences, Inc..
  - Action: appointed
  - Role: Chief Medical Officer and President of Research & Development
  source text: J. Jill Hopkins, M.D., will serve as the Company’s Chief Medical Officer and President of Research & Development, effective as of October 16, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1501796/000119312523249055/0001193125-23-249055-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.